Compare ZVRA & CCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZVRA | CCAP |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | 250 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.9M | 456.7M |
| IPO Year | 2015 | N/A |
| Metric | ZVRA | CCAP |
|---|---|---|
| Price | $9.69 | $12.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $23.00 | $15.93 |
| AVG Volume (30 Days) | ★ 777.5K | 194.9K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 13.48% |
| EPS Growth | ★ 159.21 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $106,470,000.00 | N/A |
| Revenue This Year | $37.27 | N/A |
| Revenue Next Year | $53.42 | N/A |
| P/E Ratio | ★ $7.01 | $14.18 |
| Revenue Growth | ★ 350.91 | N/A |
| 52 Week Low | $6.77 | $11.80 |
| 52 Week High | $13.16 | $16.50 |
| Indicator | ZVRA | CCAP |
|---|---|---|
| Relative Strength Index (RSI) | 55.17 | 47.77 |
| Support Level | $8.29 | $12.56 |
| Resistance Level | $9.72 | $13.48 |
| Average True Range (ATR) | 0.39 | 0.32 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 75.95 | 69.01 |
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.